Drug intelligence / Profile preview

Synuclere

Development stage: Preclinical
Lead developer: ProteoTech
Modality: Small Molecules
Administration: Oral

Overview

**Synuclere** is an investigational small molecule developed by ProteoTech for the treatment of Parkinson's disease. It targets alpha-synuclein aggregates, key pathological features in Parkinson's, by inhibiting their formation and promoting disaggregation, aiming to reduce neuronal toxicity and slow disease progression. The drug is in late-stage preclinical development, with no approved status or disclosed mechanism details beyond amyloid targeting.

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on Synuclere.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synuclere.

Explore the full profile